# A novel and inexpensive multiplex miRNA platform for liver diseases screening

> **NIH NIH R43** · KASA BIO, L.L.C. · 2024 · $273,974

## Abstract

Abstract
 Alcohol-associated liver disease (AALD) is a major driver of global liver-related morbidity and mortality.
Alcohol alone accounts for 30% to 50% of cirrhosis‐related deaths globally. At least half of people living with
type 2 diabetes have nonalcoholic fatty liver disease and are at higher risk to develop nonalcoholic or alcohol
associated steatohepatitis and cirrhosis. miRNA biomarker characterization is an emerging field for early
detection, monitoring and the evaluation of treatment response in disease conditions and clinical applications
of miRNA-based biomarkers is rapidly growing.
 Recently, miRNA-based diagnostics assays are being offered in clinical oncology that use widely
available RT-qPCR methodology. However, these assays are low throughput, and high turnaround time, due
to ability to perform analysis of only one miRNA/reaction. To date, there is no qPCR-based method available
that can detect multiple miRNAs in a single qPCR reaction. KASA BIO is developing Zip-Melt Multiplex miRNA
Solution that enables reverse transcription and detection of multiple miRNAs of interest. This novel solution
overcomes the limitations of current technologies for miRNA detection using RT-qPCR methodology. Our
proposed solution can detect multiple miRNAs from various sample matrices (tissue or body fluids) and will
provide a cost-effective, eco-friendly technology to meet the clinical requirement of multianalyte detection in a
single workflow. Compared to the existing kits, the advantage of our solution is that it is easy to use at various
research settings including resource limited setting such as point of care.
 This project proposes to develop Zip-MeltTM HepmiR Assay to determine analytical performance and
equivalence of Zip-Melt TM Multiplex miRNA Solution in comparison with commercially available RT-qPCR
Array and to use the Assay in clinical research to determine miRNA signatures important for liver diseases
(screening or diagnosis or monitoring). The proposed technology will have a significant impact on translational
research by providing an affordable multiplex miRNA qPCR solution for life sciences research and will
address the molecular diagnostic need.

## Key facts

- **NIH application ID:** 10821132
- **Project number:** 1R43AA031448-01
- **Recipient organization:** KASA BIO, L.L.C.
- **Principal Investigator:** Shashi Bala
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $273,974
- **Award type:** 1
- **Project period:** 2024-06-01 → 2026-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10821132

## Citation

> US National Institutes of Health, RePORTER application 10821132, A novel and inexpensive multiplex miRNA platform for liver diseases screening (1R43AA031448-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10821132. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*